

---

## Product Information

<b>Product SKU:</b>	IVMB0463	<b>Clone:</b>	Hu137	<b>Target:</b>	IL-6
<b>Size:</b>	100 µg			<b>Isotype:</b>	Human IgG1κ

---

## Additional Information

<b>Reactivity:</b>	Human	<b>Host Species:</b>	Human
<b>Antibody Type:</b>	Biosimilar Recombinant Human Monoclonal Antibody	<b>Expression Host:</b>	HEK-293 Cells

---

## Immunogen Information

**Background:** IL-6 and its signaling pathway play a part in immune response regulation, inflammation, and hematopoiesis.<sup>2</sup> Sarilumab is a research-grade recombinant human monoclonal IL-6 receptor antagonist. It specifically binds to both the transmembrane and soluble forms of the IL-6 receptor, thus inhibiting IL-6-mediated cis and trans-signaling in a dose-dependent manner.<sup>1</sup> Therapeutic Sarilumab, also known by the trade name Kevzara, is currently used to treat Rheumatoid Arthritis<sup>1</sup>, however, as of March 2020, The Feinstein Institute of Northwell Health publicized a study on "a human antibody that may prevent the activity" of IL-6 for the treatment of COVID-19.<sup>3</sup> Anti-Human IL-6 (Sarilumab) utilizes the same variable regions from the therapeutic antibody Sarilumab making it ideal for research projects.

**Product Concentration:** 0.2 mg/ml

**Applications:** FA

**Synonyms:** Interleukin-6, CDF; HGF; HSF; BSF2; BSF-2; IFNB2; IFN-beta-2

**Antigen Distribution:** IL-6R is ubiquitously expressed.

**Additional Applications:** IHC (Paraffin)IHC (Frozen)

**Formulation:** This DyLight 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

<b>Specificity:</b>	This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Sarilumab. Sarilumab binds to the transmembrane and soluble forms of the IL-6 receptor. This product is for research use only.
<b>Pathogen Testing:</b>	-
<b>Storage &amp; Handling:</b>	This DyLight 488 conjugate is stable when stored at 2-8°C. Do not freeze.